Skip to main content
. 2022 Nov 1;49(1):43–52. doi: 10.1093/schbul/sbac162

Table 1.

Demographic and Clinical Information of Schizophrenia Patients

Schizophrenia Patients (Cross Sectional, n = 91) Schizophrenia Patients (rTMS Treatment)
Active Group (n = 26) Sham Group (n = 26) Statistics/P-Value
Age (years) 26.0 ± 7.90 26.4 ± 8.63 26.5 ± 6.65 .05/.96
Gender (m/f) 37/54 12 ± 14 13 ± 13 .08/.78
Education (years) 12 ± 2.68 12.4 ± 2.89 12.0 ± 2.74 .49/.62
Disease Duration (years) 6.1 ± 4.95 6.7 ± 4.66 6.4 ± 5.40 .18/.86
PANSS 69.9 ± 16.90 73.4 ± 18.34 71.4 ± 16.98 .40/.69
HAMA 5.7 ± 3.20 5.0 ± 2.93 6.1 ± 3.48 1.17/.25
HAMD 5.1 ± 2.92 4.8 ± 2.36 5.7 ± 3.92 1.07/.29
Risperidone equivalent (mg) 21.6 ± 16.39 22.8 ± 15.6 23.4 ± 21.2 .12/.91

HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Scale; PANSS, the Positive and Negative Syndrome Scale; rTMS, repetitive Transcranial Magnetic Stimulation.